SCHEDULE 13G/A: Investment Funds and Harris Kupperman Disclose Significant Stake in Inmune Bio, Inc.

Praetorian Capital Fund LLC, Mongolia (Barbados) Corp., and related entities, including Harris Kupperman, have disclosed a combined beneficial ownership of 7.2% in Inmune Bio, Inc. as of March 31, 2025.

Summary

• Praetorian Capital Fund LLC, Praetorian PR LLC, Praetorian Capital Management LLC, Mongolia (Barbados) Corp., Mongolia Growth Group Ltd., and Harris Kupperman collectively reported beneficial ownership of 1,657,200 shares of Inmune Bio, Inc. common stock.
• This aggregate ownership represents approximately 7.2% of Inmune Bio, Inc.'s outstanding shares, based on 22,930,311 shares outstanding as of March 27, 2025.
• Praetorian Capital Fund LLC directly beneficially owned 1,437,200 shares, which includes 181,800 shares issuable upon exercise of warrants and 390,400 shares underlying call options, all exercisable within 60 days of March 31, 2025, representing 6.2% of the class.
• Mongolia (Barbados) Corp. directly beneficially owned 220,000 shares, including 85,000 shares underlying call options exercisable within 60 days of March 31, 2025, representing 1.0% of the class.
• Harris Kupperman, as the managing member of Praetorian PR and PCM, and CEO/Executive Chairman of MGG, is deemed to beneficially own the combined 1,657,200 shares.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information to assess company performance or future prospects, thus maintaining a neutral sentiment.

Positives

• A group of investment entities and a prominent investor, Harris Kupperman, have taken a significant beneficial ownership stake of 7.2% in Inmune Bio, Inc., potentially signaling confidence in the company's future.

Future Outlook

The document is a beneficial ownership disclosure and does not contain forward-looking statements or guidance regarding Inmune Bio, Inc.'s future outlook.

Industry Context

This filing is a standard disclosure of significant beneficial ownership by investment entities and individuals, common in the public markets. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant ownership stakes held by institutional and individual investors, which can influence market perception and trading activity.

Key Dates

Keywords

Inmune Bio Inc., Schedule 13G, beneficial ownership, Praetorian Capital Fund, Mongolia Growth Group, Harris Kupperman, common stock, investment, SEC filing